Insider buying
~$314K7,000 sh @ $44.85
Traded Feb 26, 2025 · filed 2 days later
A Crispr Therapeutics director paid $314K out of pocket for Crispr Therapeutics shares.
Ask OQRO reads the filings behind this page and answers in plain words, with a link to each source.
Ask OQRO is part of OQRO Pro. Everything else on OQRO is free.
Only to see which pages are hard to use, so we can fix them. Nothing is used for ads, and what you type stays hidden (Microsoft Clarity, PostHog). Privacy Policy
Holdings as of Dec 31, 2024 (Q4 2024) · Filed Jan 29, 2025
11 tracked managers disclosed the same change for Q4 2024. From a 13F filed Jan 29, 2025 covering holdings at Dec 31, 2024 — a quarter-end snapshot, not a live trade.
Written from the filing's own figures. OQRO describes what was reported and never tells you what to buy or sell.
Increased
Compared with the manager's Q3 2024 13F
300,589
310,270
+3.2%
Share count drives classification; reported value also moves with price
0.24%
Within the filing's reported positions, not the manager's total assets
11
For Q4 2024
Insider buying
Traded Feb 26, 2025 · filed 2 days later
A Crispr Therapeutics director paid $314K out of pocket for Crispr Therapeutics shares.
Samarth Kulkarni (Chief Executive Officer) sold ~$1.01M of Crispr Therapeutics
Planned saleSamarth Kulkarni (Chief Executive Officer) sold ~$641K of Crispr Therapeutics
Planned saleEvery dated public record OQRO holds about the company from 60 days before to 120 days after, oldest first. It shows what was going on; none of it is a stated reason for the trade.